Sorrento Therapeutics Inc (PK:SRNE)

Jun 05, 2023 09:00 am ET
Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patient
Shanghai Escugen Biotechnology Co., Ltd. (“Escugen”), a partner of Levena (Suzhou) Biopharma Co., Ltd. (“Levena”), a wholly owned subsidiary of Sorrento Therapeutics, Inc. (Sorrento), today released preliminary results from a first-in-human study...
Feb 18, 2023 08:37 pm ET
Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an IRS Form 8937 (the “Form 8937”) to supplement its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at...
Feb 17, 2023 03:47 pm ET
Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an update to its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend...
Feb 17, 2023 10:02 am ET
Thinking about buying stock in Esports Entertainment, Marathon Digital, Sorrento Therapeutics, Nu Holdings, or ContextLogic?
NEW YORK, Feb. 17, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GMBL, MARA, SRNE, NU, and WISH.
Feb 16, 2023 01:40 pm ET
Sorrento Therapeutics, Inc. Receives Court Approval for "First Day" Employee Wages and Cash Management Motions
SAN DIEGO, Feb. 16, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted approval of Sorrento's employee wages motion and interim approval of its cash management motion, in connection with Sorrento's chapter 11 petition, which was filed on February 13, 2023.  Sorrento expects to seek approval of other customary "first day" motions in the
Feb 16, 2023 09:58 am ET
Thinking about buying stock in Sorrento Therapeutics, Ambrx Biopharma, Palantir Technologies, Marathon Digital, or Paramount?
NEW YORK, Feb. 16, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, AMAM, PLTR, MARA, and PARA.
Feb 13, 2023 03:46 pm ET
Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.
Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain...
Feb 13, 2023 10:21 am ET
Thinking about buying stock in Sorrento Therapeutics, Bed Bath & Beyond, C3.ai, Expion360, or SoundHound AI?
NEW YORK, Feb. 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, BBBY, AI, XPON, and SOUN.
Feb 12, 2023 06:48 pm ET
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine
Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain...
Feb 04, 2023 10:48 pm ET
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders
Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain...
Feb 03, 2023 08:59 pm ET
Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Co
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today distributed dividend confirmation statements to 146 brokerage firms regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company (Nasdaq:...
Feb 02, 2023 02:12 pm ET
Sorrento Issues Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a supplement to its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent...
Feb 02, 2023 01:15 pm ET
Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Com
Scilex Holding Company (Nasdaq: SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a supplement to its previously issued “Frequently Asked Questions” document under the “Investors”...
Jan 29, 2023 10:26 pm ET
Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of...
Jan 29, 2023 09:55 pm ET
Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
Scilex Holding Company (Nasdaq: SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a “Frequently Asked Questions” document under the “Investors” section of its website at...
Jan 09, 2023 09:00 am ET
Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today released unblinded Phase 1b study data of its oral main viral protease (Mpro) inhibitor, OVYDSO™ (STI-1558) in COVID patients. This Phase 1b safety, PK and efficacy study in healthy...
Jan 03, 2023 07:51 am ET
Thinking about buying stock in Sorrento Therapeutics, Jasper Therapeutics, Chemomab Therapeutics, ACM Research, or Evaxion Biotech?
NEW YORK, Jan. 3, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, JSPR, CMMB, ACMR, and EVAX.
Dec 06, 2022 09:00 am ET
Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") has received clearance from the US FDA to initiate clinical trials with STI-1557, its next generation mRNA vaccine against SARS-CoV-2 Omicron variants. This mRNA vaccine incorporates a mutation...
Dec 05, 2022 03:01 pm ET
Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) is pleased to announce the results of a Phase II NK/T-cell lymphoma study of IMC-001, a PD-L1 monoclonal antibody licensed to ImmuneOncia Therapeutics, LLC (“ImmuneOncia”) (Seongnam, South...
Nov 29, 2022 02:06 pm ET
Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today released topline Phase I SAD/MAD study data of its oral main protease (Mpro) inhibitor, STI-1558, conducted in 58 healthy volunteers in Australia. In addition to the Mpro inhibition,...
Nov 13, 2022 03:02 pm ET
Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid Arthritis
Sofusa®, a wholly-owned division of Sorrento Therapeutics (Nasdaq: SRNE, “Sorrento”), today announced that it will host a virtual Key Opinion Leader (KOL) panel discussion titled “Empowering the Lymphatics: Unleashing the Potential of Biologics...
Nov 10, 2022 02:45 pm ET
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), Debuts on Nasdaq Under Ticker “SCLX”
Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management...
Nov 10, 2022 02:15 pm ET
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business C
Scilex Holding Company (Nasdaq: SCLX and SCLXW), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain...
Oct 31, 2022 09:00 am ET
Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Annou
Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and...
Oct 17, 2022 09:00 am ET
Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-1
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the completion of a Phase 1 study of its oral main viral protease (Mpro) inhibitor, the STI-1558 in 58 healthy volunteers. The Phase 1 safety and PK study in healthy volunteers...
Oct 14, 2022 02:56 pm ET
Sorrento Announces Publication of Data in Cell Press Journal Med Describing Discovery and Preclinical Efficacy of a Broadly-Acting SARS-CoV-2 Neutralizing Antibody Administered IV (STI-9167) or IN (ST
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced publication in the Cell Press journal Med of data detailing work relating to the discovery and preclinical profiling of STI-9167 neutralizing antibody activity against a broad...
Oct 06, 2022 09:00 am ET
Sorrento Therapeutics to Participate in Key Opinion Leader Panel Discussion on “New Horizons for the Treatment of Non-small Cell Lung Cancer”
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Dr. Mike A. Royal, Chief Medical Officer, will participate in an upcoming Key Opinion Leader (KOL) Panel Discussion that will focus on the great unmet need in non-small...
Sep 29, 2022 09:00 am ET
Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Pay Off of Remaining Balance of its Senior Secured Notes
Scilex Holding Company (“Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it pre-emptively...
Sep 26, 2022 09:00 am ET
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that the company has completed enrollment of its latest Phase 2 clinical study of RTX for treating moderate-to-severe osteoarthritis of the knee pain (OAK). This Phase 2...
Sep 15, 2022 03:34 pm ET
Sorrento Announces the Publication in the Nature Journal Scientific Reports the Details of the Discovery of SARS-CoV-2 Neutralizing Antibodies from the G-MAB Library
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced publication of peer-reviewed data detailing the discovery and preclinical profiling of antibodies from the Sorrento G-MAB™ library with neutralizing activity against SARS-CoV-2...
Sep 15, 2022 09:00 am ET
Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for P
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced completion of its first Phase 1b proof of concept study using the Sofusa Lymphatic Drug Delivery System (Sofusa). STI-SOFUSA-1003 is a Phase 1b proof of concept study designed...
Sep 08, 2022 09:00 am ET
Sorrento Therapeutics to Participate in Morgan Stanley 20th Annual Global Healthcare Conference September 12-14
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Henry Ji, Ph.D., Chairman, President and Chief Executive Officer, and members of Sorrento’s executive team will participate the 20th Annual Morgan Stanley Global Healthcare...
Aug 30, 2022 11:21 pm ET
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®
Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, today announced that FDA has granted fast track designation for its...
Aug 23, 2022 09:00 am ET
Sorrento Announces Significant Positive Pivotal Trial Results as Assessed by an Independent Review Committee (IRC) With Matured Long-Term (Over Three Years) Follow-Up Data of Abivertinib for the Treat
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC assessment with matured long-term follow up data....
Aug 19, 2022 09:00 am ET
Sorrento Therapeutics Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the NMPA clearance of a Phase I study of its oral main viral protease (Mpro) inhibitor, STI-1558, in subjects with COVID-19 in a MAD study in China. In a previously announced...
Aug 17, 2022 09:00 am ET
Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido® across certain designated territories in
Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, today announced the signing of a Product Distribution Agreement...
Aug 16, 2022 09:00 am ET
Scilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Work To Access An Additional 20 Million Lives With One Of The Largest National Pharmac
Scilex Holding Company (“Scilex”), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced that, effective September 1, 2022, ZTlido® (lidocaine topical system) 1.8% will be added to one of the largest national PBMs and a...
Aug 03, 2022 09:00 am ET
Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the completion of the SAD portion of the Phase 1 study of its oral main viral protease (Mpro) inhibitor, the STI-1558. The Phase 1 safety and PK study in healthy volunteers was...
Jul 19, 2022 02:53 pm ET
Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the FDA clearance of a Phase 1 study of its oral main viral protease (Mpro) inhibitor, STI-1558, in patients with impaired renal and hepatic function. A previously announced...
Jul 07, 2022 09:30 am ET
Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc.
Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid...
Jul 05, 2022 02:04 pm ET
Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors
Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid...
Jun 24, 2022 03:38 pm ET
Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of the Honorable Tommy...
Jun 14, 2022 10:33 am ET
Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treat
Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid...
Jun 03, 2022 09:20 am ET
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ri
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the first subject was dosed in a Phase I clinical study (NCT05364840) of its oral main viral protease (Mpro) inhibitor, STI-1558. The world has been experiencing repeated waves...
Jun 03, 2022 09:00 am ET
Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes
Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid...
Jun 02, 2022 09:00 am ET
Scilex Holding Company, a Sorrento Company, announces continued growth in ZTlido® in managed health care plans
Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid...
Jun 02, 2022 06:30 am ET
Caris Life Sciences, Prostate Cancer Clinical Trial Consortium and Sorrento Therapeutics Announce Collaboration to Advance Precision Medicine Development Using Comprehensive Genomic Profiling
Collaboration will comprehensively profile DNA, RNA and proteins on patient samples from the Phase 2 Maverick trial to understand mechanisms of disease response and resistance
Jun 01, 2022 09:00 am ET
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Levena Biopharma, a Sorrento Company, are to Present Positive Clinical Progress of A166, an Anti-HER2 ADC, in Treating Locally Advanced or Metasta
Sichuan Kelun-Biotech Biopharmaceutical Co, Ltd. ("Kelun-Biotech") and Levena Biopharma (“Levena”), a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), today announced the planned presentation of A166 data (Abstract #1037 and...
May 18, 2022 09:30 am ET
Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain
Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”) and a commercial biopharmaceutical company focused on developing and...
May 18, 2022 09:00 am ET
Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors
Sorrento Therapeutics, Inc (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of former Roche...
May 17, 2022 11:00 am ET
Sorrento’s License Partner, Lee’s Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its license partner, China Oncology Focus Limited (“COF”), a subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm”), has completed the patient enrollment for a...
May 17, 2022 09:00 am ET
Sorrento Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib (Fujovee™) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has received clearance from the FDA for its investigational new drug application (IND) for Abivertinib (Fujovee™) for the Phase 2 MAVERICK study to be conducted in...
May 16, 2022 09:00 am ET
Scilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission relating to the p
Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”) and Vickers Vantage Corp. I (Nasdaq: VCKA “Vickers”) today announced the filing of...
May 11, 2022 09:00 am ET
Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia
Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”) and a commercial biopharmaceutical company focused on developing and...
May 05, 2022 08:05 pm ET
Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA™) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual Meeting
Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”) and a commercial biopharmaceutical company focused on developing and...
May 03, 2022 09:15 am ET
Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breas
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its license and development partner, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun”), presented at this year’s Chinese Society of Clinical Oncology (CSCO)...
May 02, 2022 09:00 am ET
Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD™ IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its Phase I study of intranasal (IN) STI-9199 (COVISHIELDTM IN) has been fully enrolled in healthy volunteers. The study is currently still blinded and ongoing. The safety...
Apr 28, 2022 09:00 am ET
Scilex Holding Company a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., Appoints Highly Accomplished Life Science Executive, Elizabeth Czerepak, as Executive Vice President, Chief Financial
Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), who is a commercial biopharmaceutical company focused on developing and commercializing non-opioid...
Apr 27, 2022 09:00 am ET
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., to Present SP-102 (SEMDEXA™) Efficacy and Safety Data from its Pivotal Phase 3 Clinical Trial Program for Sciatica P
Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid...
Apr 25, 2022 12:46 pm ET
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Expanding Its Direct Distribution Network to National And Regional Wholesalers And Pharmacies
Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid...
Apr 25, 2022 09:30 am ET
Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2 and Other SARS-CoV-2 Variants of Concern
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has received clearance from the FDA for its investigational new drug application (IND) for intravenous (IV) STI-9167 (COVISHIELD) to study the safety and...
Apr 25, 2022 09:00 am ET
Dr. Henry Ji, Sorrento Therapeutics’ Chairman and CEO and Scilex Holding Company’s Executive Chairman, to Present at the B. Riley Securities’ 2022 Virtual Neuro & Opthalmology Healthcare Conference (A
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that Dr. Henry Ji, Chairman and CEO of Sorrento and Executive Chairman of Scilex Holding Company (“Scilex”), will participate in the B. Riley Virtual Neuro & Opthalmology...
Apr 12, 2022 09:15 pm ET
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, L
Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid...
Apr 04, 2022 09:00 am ET
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido® with preliminary gross sales of approximately $8.1 million during the m
Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid...
Apr 01, 2022 09:31 am ET
Thinking about buying stock in Sorrento Therapeutics, Energy Transfer, GameStop, Clarus Therapeutics, or Canopy Growth Corp?
NEW YORK, April 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, ET, GME, CRXT, and CGC.
Mar 31, 2022 09:00 am ET
Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients With Severe Pneumonia Due to COVID-19
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that the FDA has given clearance for Sorrento to commence the Phase 3 clinical trial of Abivertinib in severe COVID-19 patients (hospitalized patients with respiratory...
Mar 29, 2022 09:00 am ET
Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Brian Sun, M.S., J.D. as its incoming Senior...
Mar 25, 2022 09:00 am ET
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connect
Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute...
Mar 23, 2022 12:07 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mount Rainier Acquisition Corp. (Nasdaq - RNER), Brookline Capital Acquisition Corp. (Nasdaq - BCAC), Vickers V
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Mar 20, 2022 05:26 pm ET
Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and Delta Variants
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, announced today the publication of a preprint entitled “Chimeric mRNA...
Mar 18, 2022 09:00 am ET
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program fo
Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), today announced highly significant positive final results from its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program....
Mar 17, 2022 03:35 pm ET
Scilex Holding Company, a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., to Become Publicly Traded Through a Merger With Vickers Vantage Corp. I
Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute...
Mar 02, 2022 11:37 am ET
Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that new preclinical results demonstrate that pretreating an animal with intranasal neutralizing antibody (STI-9199) twenty-four (24) hours prior to being exposed to SARS-CoV-2...
Mar 02, 2022 11:24 am ET
Sorrento Announces FDA Authorization to Proceed With Phase 1 Study Of Intranasal STI-9199 (COVISHIELD), a Potent Neutralization Antibody Against Covid-19 Viruses
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has received clearance from the FDA for its investigational new drug application (IND) for intranasal (IN) STI-9199 (COVISHIELD) to study the safety and pharmacokinetics...
Feb 22, 2022 09:00 am ET
Sorrento Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that additional preclinical results demonstrate broad spectrum COVISHIELD (STI-9167) neutralizing activity against Omicron BA.1, Omicron BA.1+R346K, and the increasingly...
Feb 17, 2022 01:02 pm ET
Sorrento Announces That It Has Acquired a Majority Ownership in Diagnostic Manufacturer Zhengzhou Fortune Bioscience in Response to Increasing Worldwide Demand For COVISTIX™
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the acquisition of a majority ownership of Zhengzhou Fortune Bioscience Co., Ltd. (“FortuneBio”). This acquisition is in response to dramatically increasing demands worldwide...
Feb 01, 2022 09:00 am ET
Sorrento Completes Acquisition of Virex Health, Will Commercialize Next-Generation at-Home Diagnostic Testing That Rivals PCR-Level Sensitivity for Daily Covid-19 Tests and Early Cancer Diagnosis
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has completed the acquisition of Virex Health, Inc., a Boston, MA based company (“Virex”), spun out of the labs of Professors Mark Grinstaff and Scott Schaus at BU, on...
Jan 31, 2022 05:13 pm ET
Newman Ferrara LLP Announces Corporate Governance Investigation of Sorrento Therapeutics, Inc. – SRNE
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Sorrento Therapeutics, Inc. (“Sorrento” or the “Company”) (NASDAQ:SRNE) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).
Jan 28, 2022 09:00 am ET
Sorrento Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced its late-stage preclinical Mpro inhibitor, STI-1558, effectively inhibits Omicron virus entry and replication in cell-based assays. The world is experiencing a huge wave of...
Jan 24, 2022 09:00 am ET
Sorrento Receives Purchase Order for 10 Million Covistix Tests From Its Subsidiary Sorrento Mexico for February Delivery in Mexico
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and Sorrento Mexico today announced that COFEPRIS has given EUA approval to Sorrento Mexico to import, market and distribute COVISTIX tests directly in Mexico. COVISTIX is a sensitive platinum...
Jan 21, 2022 07:00 am ET
Sorrento Therapeutics Announces Covishield (Sti-9167), a Broad-Spectrum Neutralizing Antibody, Potently Neutralizes Omicron and Omicron (+R346k) Variants of Sars-Cov-2
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the release of new data on the Omicron variant neutralizing antibody (nAb) STI-9167, COVISHIELD, an advanced stage antibody discovered and developed for clinical trials in an...
Jan 20, 2022 08:00 am ET
SORRENTO THERAPEUTICS ANNOUNCES COVISHIELD (STI-9167), A BROAD-SPECTRUM NEUTRALIZING ANTIBODY, POTENTLY NEUTRALIZES OMICRON AND OMICRON (+R346K) VARIANTS OF SARS-COV-2
SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the release of new data on the Omicron variant neutralizing antibody (nAb) STI-9167, COVISHIELD, an advanced stage antibody discovered and developed for clinical trials in an ongoing collaboration between immunologists and virologists at Sorrento and the Icahn School of Medicine at Mount Sinai ("Icahn Mount Sinai") in New York, NY.
Jan 19, 2022 02:26 pm ET
Sorrento Announces That Sorrento Mexico Has Sold Out of One Million COVISTIX Tests Last Week in Mexico
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and Sorrento Mexico today announced that approximately 1,000,000 COVISTIX tests were distributed last week in Mexico. Orders are increasing daily as pent-up demand is high for a sensitive and...
Jan 19, 2022 10:35 am ET
Sorrento Announces Completion of Enrollment in US Phase 2 Clinical Trial for COVI-DROPS and Achievement of Interim Analysis Threshold in the UK
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the US Phase 2 study (www.ClinicalTrials.gov  NCT04906694) with intranasal COVI-DROPS treatment in COVID-19 outpatients has completed enrollment. This preliminary efficacy...
Jan 18, 2022 09:00 am ET
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler)
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a PHASE 2A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF INTRAVENOUS ALLOGENEIC ADIPOSE-DERIVED...
Jan 13, 2022 10:14 am ET
Sorrento Therapeutics Mexico Wins Tender to Sell COVISTIX Tests to Mexico City Government
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today Sorrento Therapeutics Mexico (“Sorrento Mexico”), a Sorrento company, has won the first tender offer yesterday by the Mexico City Municipal Government for the purchase of...
Jan 07, 2022 05:00 pm ET
Sorrento Therapeutics Announces the Unexpected Death of its Chief Financial Officer
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the unexpected passing of Mr. Najjam Asghar, Chief Financial Officer and Senior Vice President. Mr. Asghar died of apparent natural causes on January 6, 2022. "Sorrento is...
Jan 07, 2022 11:20 am ET
Dr. Henry Ji to Present at HC Wainwright BIOCONNECT Virtual Conference (January 10th – 13th)
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: HC Wainwright BIOCONNECT Virtual ConferencePresentation will be available on...
Jan 04, 2022 09:00 am ET
Dr. Henry Ji to Participate in Longwood Healthcare Leaders Winter Webconference Panel on January 6th 2022
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming panel at the Longwood Healthcare Leaders Winter Conference: January 6th at 11:50 am PT / 2:50...
Dec 27, 2021 09:20 am ET
Sorrento Announces COVISTIX COVID-19 Virus Rapid Antigen Detection Test Detects the Omicron Variant
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that initial testing of COVISTIX on recombinant N proteins demonstrated its ability to detect the Omicron variant, in addition to detecting the original SARS-CoV-2 virus and its...
Dec 27, 2021 09:00 am ET
Sorrento Therapeutics Mexico Executes Second Contract for Sale of 10 Million COVISTIX Tests for Mexico Market
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today its subsidiary, Sorrento Therapeutics Mexico (“Sorrento Mexico”), has executed a second contract with a large distributor for the sale and distribution of up to 10 million...
Dec 20, 2021 09:00 am ET
Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the U.S. Food and Drug Administration (FDA) has granted clearance to proceed with a Phase 1b clinical trial using STI-1386, Seprehvec™, entitled “Dose Escalation Study of...
Dec 09, 2021 09:00 am ET
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.
Scilex Holding Company (“Scilex”), a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), today announced highly significant positive top-line results from its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program, a...
Dec 07, 2021 01:42 pm ET
Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Phase 2 clinical study of RTX for treating knee pain from osteoarthritis (OA) has begun enrollment. This study is a multi-center, double blind, placebo- and...
Dec 07, 2021 09:00 am ET
Sorrento Therapeutics’ Clinical Laboratory Receives Accreditation From the College of American Pathologists
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Sorrento’s Clinical Laboratory, located in San Diego, California, based on...
Dec 06, 2021 02:41 pm ET
Sorrento Receives Orders of COVISTIX for Commercial Launch in Brazil
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that initial loading orders have been processed and scheduled for delivery later this year. The initial shipment will establish an in-country safety stock to manage just in time...
Dec 06, 2021 09:00 am ET
Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (“SPAC”) Enter into Letter of Intent for Proposed Business Combination
Scilex Holding Company (“Scilex”), a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I, a Cayman Islands corporation (NASDAQ: VCKA) (“SPAC”), today announced the signing of a letter of intent for a...
Dec 05, 2021 02:28 pm ET
Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omic
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors with potent activities for both MPro and cathepsin L, a key host enzyme for SARS-CoV-2 entry into...
Nov 30, 2021 09:00 am ET
Dr. Henry Ji to Participate in the CEO Fireside Chat Evercore ISI 4th Annual HealthCONx Conference
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: Evercore ISI 4th Annual HealthCONx ConferenceWednesday, December 1, 2021 at...
Nov 29, 2021 09:00 am ET
Sorrento Publishes an Abivertinib Teaser Entitled “Abivertinib – A Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases”
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the publication of a Teaser titled “Abivertinib – a Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases” (“Abivertinib Teaser”). Sorrento intends to use the...
Nov 22, 2021 02:53 pm ET
Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today its subsidiary, Sorrento Therapeutics Mexico, has executed a contract with a leading local distributor for the sale and distribution of up to 5 million COVI-STIX™ tests for the...
Nov 12, 2021 03:19 pm ET
Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening of COVID-19 of all Convention Attendees with COVI-STIX at the 59th World Boxing Council Convention in Mexico Cit
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and the World Boxing Council (“WBC”) announced today that Sorrento’s COVI-STIX COVID-19 Virus Rapid Antigen Detection Test (“COVI-STIX”) will be used for screening all attendees of the upcoming...
Nov 12, 2021 09:00 am ET
Sorrento Announces Publication of Significant Positive Pivotal Trial Results of Abivertinib for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in the Peer-Reviewed Journal Clinical Cancer Researc
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the peer-reviewed publication of significant results from a pivotal study of abivertinib on 227 heavily pretreated NSCLC patients in the journal Clinical Cancer Research,...
Nov 07, 2021 01:08 pm ET
Sorrento Awarded California Competes Tax Credit
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the California Competes Tax Credit Committee has approved the California Competes Tax Credit Allocation Agreement (the “Agreement”) between Sorrento and the California...
Nov 03, 2021 10:06 am ET
Sorrento Receives Brazilian Health Regulatory Agency (ANVISA) Approval for COVISTIX™ (COVID-19 Virus Antigen Detection Test) for Brazil
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of approval from the Brazilian regulatory agency (ANVISA) for COVISTIX in Brazil. COVISTIX manufacturing approval (for good manufacturing practices) from ANVISA was...
Nov 01, 2021 09:00 am ET
Sorrento’s License Partner, Lee’s Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its license partner, China Oncology Focus Limited (COF), an affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharma, HKEX: 950) has submitted a NDA (new drug...
Oct 27, 2021 02:26 pm ET
Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today positive preliminary results from two Phase 2 studies designed to identify the hospitalized patient population suffering from COVID-19-induced pneumonia and respiratory...
Oct 20, 2021 01:37 pm ET
Sorrento Announces That COVISTIX™ (COVID-19 Virus Rapid Antigen Detection Test) Has Received a CE Mark and Registration of the Device
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has received an official CE Mark for COVISTIX and a Registration Number: BE/CA01/1-17633-00001-IVD. COVISTIX is a sensitive and rapid (approximately 15-minute)...
Oct 13, 2021 09:30 am ET
Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) for multiple solid tumors
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") previously announced that its partner Escugen Biotechnology Co, Ltd. (“Escugen”) and Sorrento’s subsidiary Levena (Suzhou) Biopharma Co., Ltd. (“Levena”) had received an approval letter from...
Oct 13, 2021 09:00 am ET
FDA Authorizes Sorrento Phase 2 Trial of Epidural Resiniferatoxin for the Orphan Indication of Control of Intractable Cancer Pain
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced that the company has received FDA clearance to proceed with a global Phase 2 clinical study of resiniferatoxin (RTX), entitled “A Multicenter, Phase 2 Study to Assess the Safety and...
Sep 28, 2021 12:23 pm ET
Sorrento to Participate in the Benzinga Healthcare Small Cap Conference on September 30th
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") is pleased to announce that Dr. Henry Ji, Chairman and CEO, will be participating in the Benzinga Healthcare Small Cap Conference. Dr. Ji will be providing company updates at 11:30 AM ET...
Sep 27, 2021 01:13 pm ET
Dr. Henry Ji, Sorrento Chairman and CEO, to Participate in the Virtual Cantor Global Healthcare Conference on September 29th, 2021
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that it will participate in the Cantor Virtual Healthcare Conference. Dr Henry Ji, Chairman and CEO will be presenting on Wednesday September 29th at 9:20 AM EST. Interested...
Sep 19, 2021 02:58 pm ET
Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX as Compared to a Globall
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19, today announced impressive...
Sep 13, 2021 09:00 am ET
Dr. Henry Ji, Sorrento Chairman and CEO, to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the H.C. Wainwright 23rd Global Investment Conference (www.hcwevents.com/annualconference). The conference is being...
Sep 02, 2021 11:34 am ET
Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today the start of enrollment in its Phase 2 efficacy study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute...
Aug 26, 2021 03:42 pm ET
Sorrento Exercises Exclusive Option Agreement With Texas A&M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has notified The Texas A&M University System (“TAMUS”) of its exercise of the option to an exclusive license for the global development and commercialization of highly...
Aug 26, 2021 12:28 pm ET
Sorrento Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19, today announced promising...
Aug 24, 2021 10:44 am ET
Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A&M University
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has entered into an option agreement (“Option”) with The Texas A&M University System (“TAMUS”) for exclusive rights to the intellectual property covering highly potent...
Aug 23, 2021 03:52 pm ET
Sorrento Publishes Positive Initial Results of SOFUSA® Lymphatic Drug Delivery System in a Phase 1b Rheumatoid Arthritis Study Using Enbrel
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today released a patient case report on the lymphatic delivery of Enbrel using the Sofusa Lymphatic Delivery System (SOFUSA), which has been submitted for preprint as CASE REPORT: Lymphatic...
Aug 19, 2021 04:21 pm ET
Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of C
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, released today a preprint publication, which is accessible at:...
Aug 19, 2021 09:00 am ET
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives
Scilex Holding Company (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), announced that, effective September 1, 2021, ZTlido® (lidocaine topical system) 1.8% has been added to multiple formularies, including two national PBMs...
Aug 11, 2021 09:00 am ET
Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; “Sorrento”), a clinical stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, and Dyadic International, Inc. (NASDAQ: DYAI; “Dyadic”), a global biotechnology company...
Aug 11, 2021 08:35 am ET
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate...
Aug 09, 2021 02:39 pm ET
Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, announced today the availability of a presentation on its corporate...
Aug 04, 2021 12:57 pm ET
Sorrento Announces Promising Results in a Publication Detailing of Salicyn-30 and Other Salicylanilides in Reducing SARS-CoV‑2 Replication and Suppressing Induction of Inflammatory Cytokines in a Rode
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), in collaboration with The Scripps Research Institute of La Jolla, today announced that the American Chemical Society has published the article “Salicylanilides Reduce SARS-CoV-2 Replication...
Aug 03, 2021 09:00 am ET
Sorrento Mexico and the National Institute of Genomic Medicine (INMEGEN) of Mexico Government Execute Memorandum of Understanding (MOU) for Rapid Clinical Development of COVID-19 Diagnostics, Therapeu
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its subsidiary company, Sorrento Therapeutics Mexico (“Sorrento Mexico”), has entered into an MOU agreement with the National Institute of Genomic Medicine INMEGEN...
Aug 02, 2021 09:00 am ET
Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, "Off-the-Shelf", Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractor
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the FDA has authorized Sorrento’s IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen Receptor (DAR) - T Cell therapy for relapsed...
Jul 23, 2021 11:37 am ET
Lee’s Pharmaceutical Announces First Patient Dosed With its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, as a First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and Lee’s Pharmaceutical Holdings Limited (HKEX: 950, “Lee’s Pharm”) announced today that, on July 15, 2021, China Oncology Focus Limited (“COF”), a subsidiary of Lee’s Pharm, has enrolled the...
Jul 21, 2021 02:09 pm ET
Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug Conjugate For Multiple Solid Tumors
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today its partner Escugen Biotechnology Co, Ltd. (“Escugen”) and Sorrento’s subsidiary Levena (Suzhou) Biopharma Co., Ltd. (“Levena”) have received an approval letter from the Center...
Jul 21, 2021 09:16 am ET
Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that COVID-19 patients have been dosed in its Phase 2 efficacy trial. Approximately 350 outpatients with COVID-19 who are asymptomatic or have mild symptoms will be enrolled in...
Jul 20, 2021 03:29 pm ET
Sorrento Therapeutics Announces the Formation of Sorrento Therapeutics Mexico for Commercialization of COVI-STIX and Development of Sorrento’s Portfolio of COVID-19 Products in Mexico and Parts of Lat
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has formed a subsidiary company based in Mexico City, Sorrento Therapeutics Mexico (“Sorrento Mexico”), to support the clinical development and registration of multiple...
Jul 20, 2021 12:53 pm ET
Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management
Scilex Holding Company (“Scilex”), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), today announced complete enrollment of SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program, a corticosteroid injectable...
Jul 20, 2021 09:00 am ET
Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
Sorrento Therapeutics (Nasdaq: SRNE) announced today that its partner Mabpharm Ltd (HK:2181) has received approval of its New Drug Application for its infliximab biobetter antibody in China. Sorrento holds exclusive commercial rights to this...
Jul 06, 2021 02:34 pm ET
FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that the company has received FDA clearance to proceed with a Phase 2 clinical study of RTX for treating moderate-to-severe osteoarthritis of the knee pain (OAK). The phase 2...
Jul 02, 2021 10:45 am ET
Thinking about buying stock in Iterum Therapeutics, Bridgeline Digital, T.A.T. Technologies, VEON, or Sorrento Therapeutics?
NEW YORK, July 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ITRM, BLIN, TATT, VEON, and SRNE.
Jun 25, 2021 09:31 am ET
Thinking about buying stock in Osmotica Pharmaceuticals, Property Solutions Acquisition, Sio Gene Therapies, Clearside Biomedical, or Sorrento Therapeutics?
NEW YORK, June 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OSMT, PSAC, SIOX, CLSD, and SRNE.
Jun 24, 2021 01:13 pm ET
Sorrento Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX™ (COVID-19 Virus Rapid Antigen Detection Test) and Plans Product Launch With Initial Shipments in July
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that following its receipt of EUA approval from COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) under registration number “OFICIO: CAS/10720/2021”, it...
Jun 22, 2021 01:46 pm ET
Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit – No. 3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a broad multi-year Cooperative Research and Development Agreement (CRADA) with NAMRU-3. Under the terms of the agreement, NAMRU-3 will conduct surveillance and clinical...
Jun 22, 2021 09:00 am ET
Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced completion of enrollment for its Phase 2 clinical trial of Abivertinib in hospitalized COVID-19 patients in Brazil. This study completion follows the recently completed...
Jun 14, 2021 09:31 am ET
Thinking about buying stock in Mereo BioPharma, Lipocine, Lordstown Motors, Sorrento Therapeutics, or Axcella Health?
NEW YORK, June 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MREO, LPCN, RIDE, SRNE, and AXLA.
Jun 11, 2021 04:11 pm ET
Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Medicines and Healthcare products Regulatory Agency (MHRA), the United Kingdom’s regulatory agency, has cleared Sorrento’s COVI-DROPS product candidate for a Phase 2...
Jun 11, 2021 09:00 am ET
Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients W
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a research collaboration agreement with Mayo Clinic to conduct human clinical proof of concept studies using the Sofusa Lymphatic Drug Delivery System (S-LDDS) technology across...
Jun 04, 2021 03:13 pm ET
Sorrento Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166, a Novel HER2 ADC for Advanced HER2 Positive Breast Cancers
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun”), a license and development partner, will present posters at this year’s American Society of Clinical Oncology...
Jun 04, 2021 01:00 pm ET
Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Brin
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Company has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at the Department of Medicine, Huddinge,...
Jun 02, 2021 09:00 am ET
Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has completed the acquisition of ACEA Therapeutics Inc. (“ACEA”). The merger was completed on June 1, 2021 and at such time, ACEA became a wholly owned subsidiary of...
Jun 02, 2021 07:00 am ET
Sorrento Announces Addition of COVI-STIX™ (Covid-19 Virus Rapid Antigen Detection Test) to the Official Mexican Government List of Emergency Use Approved Point of Care Rapid Antigen Tests
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Mexican Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), the health regulatory authority for Mexico, has listed COVI-STIX on its official...
May 20, 2021 09:00 am ET
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 Pivotal clinical trial of COVI-MSC™, an injectable infusion of mesenchymal stem...
May 19, 2021 09:30 pm ET
Sorrento Reports Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the first patient has been treated in a Phase 1b proof-of-concept, open-label study to assess the safety and pilot efficacy of Enbrel administered by the Sofusa Lymphatic...
Apr 27, 2021 11:39 am ET
Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma
Over the last several months, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and its development partners have advanced into clinical development (Phase 1b through Phase 3 clinical trials) a number of fully human monoclonal antibodies...
Apr 20, 2021 09:00 am ET
Sorrento Announces Positive Results of Phase 1b Study of COVI-MSC™ Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today the completion of enrollment in its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) infusions to treat COVID-19 induced acute respiratory...
Apr 09, 2021 10:50 pm ET
SORRENTO INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sorrento Therapeutics, Inc. - SRNE
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sorrento Therapeutics, Inc. (NasdaqGS: SRNE).
Apr 09, 2021 03:00 pm ET
Scilex Holding, a Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for ZTlido® Label Expansion
Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental new drug application (sNDA) approval from the FDA for ZTlido® to make efficacy labeling change with clinical...
Apr 05, 2021 09:00 am ET
Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the signing of a merger agreement pursuant to which Sorrento will acquire ACEA Therapeutics, Inc. (“ACEA”). The acquisition will include late clinical stage drug Abivertinib,...
Mar 25, 2021 03:58 pm ET
Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today updated positive results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute...
Mar 18, 2021 09:00 am ET
Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the first patient has been treated in its Phase 1b Amyloid Light Chain (AL) Amyloidosis study of STI-6129, an ADC which uses STI-5171, a fully human monoclonal antibody...
Mar 17, 2021 01:00 am ET
Dr. Henry Ji to Participate in the CEO Roundtable during WuXi Healthcare Forum 2021 on March 17, 2021
Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: CEO Roundtable during WuXi Healthcare Forum 2021 Dr. Henry Ji will participate in the CEO...
Mar 09, 2021 09:00 am ET
Sorrento and Mount Sinai Health System Enter Into Exclusive License Agreement for Development of Potent Antibody Combinations Aimed at Neutralizing SARS-CoV-2 and the Emerging United Kingdom and South
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced major progress in the development of COVISHIELD through the license of intellectual property developed by the scientific team at the Icahn School of Medicine at Mount Sinai...
Mar 07, 2021 10:27 pm ET
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Ce
China Oncology Focus Limited (COF), an affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharm, HKEX: 950) announced that its anti-PD-L1 antibody, Socazolimab, licensed from Sorrento to COF for the greater China territory, has been cleared...
Mar 05, 2021 01:06 am ET
Dr. Henry Ji to Participate in the H.C. Wainwright Virtual GLOBAL LIFE SCIENCES CONFERENCE 2021 Investor Conference
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: H.C. WAINWRIGHT Global Life Sciences 2021 (Virtual Conference)Sorrento’s Corporate...
Mar 02, 2021 04:02 pm ET
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has received clearance from the FDA for its Investigational New Drug application (IND) for its Phase 1 study of the safety and pharmacokinetics of intranasal (IN)...
Mar 02, 2021 09:00 am ET
Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Treatment of Multiple Malignancies
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the FDA has cleared Sorrento’s internally developed anti-CD47 monoclonal antibody, STI-6643, which was discovered from Sorrento's G-MAB™ library, for an initial clinical...
Mar 01, 2021 12:21 pm ET
Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chroni
Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”) and Scilex Holdings Company (“Scilex”), a majority owned subsidiary of Sorrento, have entered into an exclusive licensing term sheet with Aardvark Therapeutics (“Aardvark”) to acquire Aardvark’s...
Feb 26, 2021 10:50 pm ET
SORRENTO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sorrento Therapeutics, Inc. - SRNE
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sorrento Therapeutics, Inc. (NasdaqGS: SRNE).
Feb 22, 2021 08:31 am ET
Thinking about buying stock in GameStop, Verb Technology, Brickell Biotech, Creative Realities, or Sorrento Therapeutics?
NEW YORK, Feb. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GME, VERB, BBI, CREX, and SRNE.
Feb 09, 2021 09:00 am ET
Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China for the Treatment of Recurrent or Metastatic
China Oncology Focus Limited (COF), an affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharma, HKEX: 950), and Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE), today announced that its anti-PD-L1 antibody, socazolimab, licensed from...
Feb 08, 2021 03:21 pm ET
Sorrento Announces Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License Fro
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the formation of ADNAB, Inc., a subsidiary Company, that will develop and commercialize a Mayo Clinic-developed technology platform for the manufacture of antibody-drug...
Feb 01, 2021 08:31 am ET
Thinking about buying stock in First Majestic Silver, Dynavax Technologies, AMC Entertainment, McEwen Mining, or Sorrento Therapeutics?
NEW YORK, Feb. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AG, DVAX, AMC, MUX, and SRNE.
Jan 31, 2021 05:27 pm ET
Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today additional positive results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute...
Jan 29, 2021 08:31 am ET
Thinking about buying stock in Nokia, Sorrento Therapeutics, BlackBerry, Viveve Medical, or Jaguar Health?
NEW YORK, Jan. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOK, SRNE, BB, VIVE, and JAGX.
Jan 28, 2021 10:05 am ET
Thinking about buying stock in Nokia, AMC Entertainment, BlackBerry, Northern Dynasty Minerals, or Sorrento Therapeutics?
NEW YORK, Jan. 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOK, AMC, BB, NAK, and SRNE.
Jan 27, 2021 08:31 am ET
Thinking about buying stock in Clovis Oncology, Ashford Hospitality Trust, Atara Biotherapeutics, Sorrento Therapeutics, or Vertex Energy?
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVS, AHT, ATRA, SRNE, and VTNR.
Jan 26, 2021 07:09 pm ET
Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today positive preliminary results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute...
Jan 19, 2021 05:05 pm ET
Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced that it will be presenting preliminary results from an ongoing SARS-CoV-2 mutation surveillance program for its neutralizing antibodies currently in clinical and pre-clinical...
Jan 19, 2021 07:30 am ET
Thinking about buying stock in DBV Technologies, Endra Life Sciences, Precision BioSciences, Sorrento Therapeutics, or Aldeyra Therapeutics?
NEW YORK, Jan. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DBVT, NDRA, DTIL, SRNE, and ALDX.
Jan 19, 2021 02:05 am ET
Dr. Henry Ji to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 20, 2021
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: Fireside chat during the B. Riley Securities Oncology Investor Conference being...
Jan 15, 2021 09:45 am ET
Thinking about buying stock in Sundial Growers, Charah Solutions, Sorrento Therapeutics, Zomedica, or Novan?
NEW YORK, Jan. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, CHRA, SRNE, ZOM, and NOVN.
Jan 10, 2021 05:58 pm ET
Dr. Henry Ji to Participate in the H.C. Wainwright Bioconnect 2021 Virtual Investor Conference
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: H.C. WAINWRIGHT BIOCONNECT 2021 January 11-14, 2021 (Virtual Conference)Sorrento’s...
Jan 08, 2021 08:31 am ET
Thinking about trading options or stock in Nio, Plug Power, Pfizer, Sorrento Therapeutics, or BioNTech?
NEW YORK, Jan. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, PLUG, PFE, SRNE, and BNTX.
Dec 30, 2020 12:47 pm ET
Sorrento Announces the Submission of a Marketing Authorization Application to COFEPRIS (Mexico) for COVI-STIX™ Rapid Detection Test of SARS-CoV-2 Viral Antigen
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that a Marketing Authorization Application has been submitted by its agents in Mexico to Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), the health...
Dec 22, 2020 06:59 pm ET
Sorrento Announces It Has Submitted An Emergency Use Authorization (EUA) Application to the FDA for COVI-STIX™ Rapid Test for the Detection of SARS-CoV-2 Viral Antigen
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that an Emergency Use Authorization (EUA) Application has been submitted to the US Food and Drug Administration for its COVI-STIX rapid diagnostic test for the detection of the...
Dec 09, 2020 09:00 am ET
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in Healthy Volunteers and in Newly Diagnosed COVID-19 Patients
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today FDA acceptance of its Investigational New Drug (IND) application for its Phase 1 clinical trials for intravenous (IV) STI-2020 (COVI-AMG). The trials will evaluate the safety,...
Dec 09, 2020 07:30 am ET
Thinking about buying stock in Rocket Pharmaceuticals, Sorrento Therapeutics, Intec Pharma, Cinedigm Corp, or Curis Inc?
NEW YORK, Dec. 9, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RCKT, SRNE, NTEC, CIDM, and CRIS.
Dec 08, 2020 08:05 pm ET
Sorrento Receives Licensure From the State of California for Clinical Testing Laboratory (CLIA) Allowing for Clinical Sample Testing
approved test using nasal pharyngeal swab - Laboratory developed test (COVI-STIX™) using shallow nasal swab - Laboratory developed test (COVI-TRACE™) using shallow nasal swab SAN DIEGO, Dec. 08, 2020 (GLOBE...
Nov 30, 2020 09:45 am ET
Thinking about buying stock in AMC Entertainment, Inovio Pharmaceuticals, Sundial Growers, Nikola Corp, or Sorrento Therapeutics?
NEW YORK, Nov. 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, INO, SNDL, NKLA, and SRNE.
Nov 29, 2020 08:19 pm ET
Sorrento to Participate in the 32nd Piper Sandler Healthcare Investor Conference
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), is pleased to announce that Dr. Henry Ji, Chairman and CEO, will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference. A pre-recorded presentation is made available...
Nov 27, 2020 08:31 am ET
Thinking about buying stock in Sorrento Therapeutics, Blink Charging, Dolphin Entertainment, FuelCell Energy, or Gevo Inc?
NEW YORK, Nov. 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, BLNK, DLPN, FCEL, and GEVO.
Nov 27, 2020 08:00 am ET
DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies
SmartPharm Therapeutics, Inc. (“SmartPharm”), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and developer of next-generation, non-viral gene therapy technologies, announced today that it has been awarded a...
Nov 20, 2020 08:31 am ET
Thinking about buying stock in Sorrento Therapeutics, Blink Charging, AMC Entertainment, 22nd Century Group, or Sunworks?
NEW YORK, Nov. 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, BLNK, AMC, XXII, and SUNW.
Nov 11, 2020 09:55 am ET
Should you invest in American Airlines, Microsoft, Plug Power, Sorrento Therapeutics, or Moderna?
NEW YORK, Nov. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAL, MSFT, PLUG, SRNE, and MRNA.
Nov 11, 2020 09:00 am ET
Sorrento Announces IND Filing for COVI-DROPS, an Intranasal Formulation of a High Potency Neutralizing Antibody Against SARS-CoV-2
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it is filing an investigational new drug application (IND) for intranasal (IN) COVI-DROPS (STI-2099) to study the safety and pharmacokinetics in both healthy volunteers and...
Nov 09, 2020 09:00 am ET
Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it is filing an investigational new drug application (IND) for intravenous (IV) COVI-AMG (STI-2020) to treat COVID-19 patients with mild symptoms and to evaluate safety and...
Nov 03, 2020 08:31 am ET
Thinking about buying stock in O2Micro International, Sasol Limited, 3D Systems, Cronos Group, or Sorrento Therapeutics?
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OIIM, SSL, DDD, CRON, and SRNE.
Oct 29, 2020 09:00 am ET
Sorrento Announces That Intranasal Administration of COVI-AMG™ Neutralizing Antibody Prevented COVID-19 Disease Progression in Infected Hamsters Following SARS-CoV-2 Infection
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) previously released preclinical data about intravenous COVI-AMG™ (STI-2020; Affinity Matured COVI-GUARD) neutralizing antibody (nAb) in a preprint publication, which can be found at...
Oct 14, 2020 11:56 am ET
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 clinical trial of Abivertinib in mild, moderate and severe COVID-19 patients. The...
Oct 12, 2020 05:20 pm ET
Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue Therapies
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has entered into an exclusive license agreement with Personalized Stem Cells, Inc. (PSC) to acquire global rights to its adipose derived mesenchymal stem cells (MSCs)...
Oct 09, 2020 07:46 pm ET
Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today released details about its upcoming COVID-19 Pipeline Update call and webcast on October 13th, 2020. Title: Sorrento Therapeutics COVID-19 Pipeline Update, R&D Discussion and...
Oct 07, 2020 03:09 pm ET
Sorrento Announces the Discovery of Salicyn-30 Small Molecule That Strongly Inhibits SARS-CoV-2 Infection in Preclinical Studies and Highlights its Place in a Potential Multi-Modal Therapy Strategy in
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has discovered a small molecule termed Salicyn-30 that demonstrated a potent 3-4 log reduction of SARS-CoV-2 virus infection in an in vitro virus infection experiment....
Oct 07, 2020 06:00 am ET
Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in
Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), today announced continuous sales growth in ZTlido® from quarter to quarter in 2020. Scilex expects third quarter 2020 ZTlido®...
Oct 04, 2020 06:39 pm ET
Sorrento to Host a R&D Day to Showcase COVID-19 Product Pipeline
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced it will host a R&D Day conference call and simultaneous webcast on October 13th, 2020 focusing on its comprehensive multi-modal approach to COVID-19. During this...
Sep 30, 2020 09:26 am ET
SORRENTO THERAPEUTICS AND VIRALCLEAR ENTER INTO AGREEMENT TO EXPLORE THE COMBINATION OF ANTIBODY AND ANTIVIRAL ASSETS AGAINST COVID-19
Sorrento to initiate testing with a selection of its agents in combination with ViralClear’s anti-viral compound for possible synergistic anti-viral effect against SARS-CoV-2 in the preclinical model of Golden Syrian hamster.ViralClear to...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.